- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02037945
18F-Fluorocholine (18F-FCho) to Distinguish Necrosis From Recurrence in Brain Metastases
December 15, 2022 updated by: Memorial Sloan Kettering Cancer Center
The main purpose of this study is to determine the distribution of 18F Fluorocholine (18F-FCH) in the brain which can help distinguishing radiation-induced scarring from tumor regrowth.
In addition, the study will measure levels of 18F-FCH in the blood and (if applicable) in the brain lesion tissue that is removed as part of the planned brain surgery.
Study Overview
Study Type
Interventional
Enrollment (Actual)
19
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
New York, New York, United States, 10065
- Memorial Sloan Kettering Cancer Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patient and/or guardian is able to provide written informed consent prior to study registration
- Age ≥ 21 years old
- Evolving brain lesions post SRS requiring neurosurgical resection (whether for symptomatic control or to establish pathology)
Exclusion Criteria:
- Inability to undergo a MRI or PET scan (e.g., claustrophobia or metal implant)
- Pregnant or nursing female
- Unable to cooperate for PET/CT
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: pts with brain mets going for surgery
This study will enroll patients with brain metastases that are evolving after SRS who are scheduled to undergo surgical resection.
Eligible patients will undergo an 18F-FCH PET study 1-to-7 days pre-operatively.
Although no toxicity has been previously reported following 18F-FCH administration, patients will be contacted 1-3 days after their scan and asked whether they experienced any adverse effects.
The patients who have a positive 18F-FCH PET study (in which there is visible focal "hot spots" (a focus of lesion/normal white matter ratio >1.4) of 18F-FCH) will undergo further evaluation and be administered a second administration oflower activity 18F-FCH at the time of surgery.
The purpose of the second 18F-FCH administration in the operating room is to further elucidate the tissue distribution of 18F-FCH radioactivity with respect to the histopathology of the surgically resected tissue.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
to distinguish radiation necrosis from progressive tumor
Time Frame: 1 year
|
by comparing the PET imaging results to the surgical pathology
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Kathryn Beal, MD, Memorial Sloan Kettering Cancer Center
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2014
Primary Completion (Actual)
December 8, 2022
Study Completion (Actual)
December 8, 2022
Study Registration Dates
First Submitted
January 14, 2014
First Submitted That Met QC Criteria
January 14, 2014
First Posted (Estimate)
January 16, 2014
Study Record Updates
Last Update Posted (Actual)
December 19, 2022
Last Update Submitted That Met QC Criteria
December 15, 2022
Last Verified
December 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 13-199
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Brain Metastases
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingRecurrent Brain Metastases | Progressive Brain MetastasesUnited States
-
AC Camargo Cancer CenterCarl Zeiss Meditec AGTerminatedBrain Metastases, Adult | Central Nervous System MetastasesBrazil
-
University of Vermont Medical CenterRecruiting
-
University Hospital, BrestRecruiting
-
Ohio State University Comprehensive Cancer CenterRecruitingBrain Metastases, AdultUnited States
-
Allegheny Singer Research Institute (also known...Elekta LimitedRecruitingBrain Metastases, AdultUnited States
-
BioMimetix JV, LLCNational Cancer Institute (NCI); Duke Cancer InstituteTerminatedMultiple Brain MetastasesUnited States
-
Guangdong 999 Brain HospitalJinan University Guangzhou; Beijing Tricision Biotherapeutics Inc; Trinomab Biotech...CompletedBrain Cancer | Neoplasm MetastasesChina
-
Royal Marsden NHS Foundation TrustNational Institute for Health Research, United KingdomUnknown
-
Rigshospitalet, DenmarkRecruitingCancer | Brain Metastases, AdultDenmark
Clinical Trials on 18F-FCH PET Scan
-
University Health Network, TorontoProstate Cancer CanadaCompleted
-
Lawson Health Research InstituteCanadian Institutes of Health Research (CIHR)Completed
-
Sir Mortimer B. Davis - Jewish General HospitalCompletedProstate CancerCanada
-
Lawson Health Research InstituteCompletedProstate CancerUnited Kingdom, Australia, Canada
-
Imperial College LondonMedical Research Council; ECMCRecruitingMetastatic Breast Cancer | HER2-negative Breast Cancer | ER Positive Breast CancerUnited Kingdom
-
Sir Mortimer B. Davis - Jewish General HospitalCompletedProstate CancerCanada
-
Centre for Addiction and Mental HealthActive, not recruiting
-
M.D. Anderson Cancer CenterWithdrawnHead and Neck Neoplasms | Metastases, Neoplasm | Squamous Cell CarcinomaUnited States
-
Northwell HealthRecruitingAlzheimer Disease | Alzheimer Disease With Delusions | Alzheimer Disease With PsychosisUnited States